How many investments has Novo Holdings made?

Novo Holdings has 28 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.

What stage does Novo Holdings invest at?

Novo Holdings invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Novo Holdings's typical check size?

Novo Holdings typically writes checks of $1.1M – $54M.

What sectors does Novo Holdings focus on?

Novo Holdings focuses on AgTech, Biotech, Cleantech, Climate Tech, Digital Health, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.

Where is Novo Holdings located?

Novo Holdings is headquartered in Copenhagen, DK.

Does Novo Holdings lead rounds?

Novo Holdings has led 7 of the 14 rounds where its role is on record.

Who does Novo Holdings co-invest with?

Novo Holdings most often shares deals with Jeito Capital, Industrifonden, OrbiMed, among 41 tracked co-investors.

Novo Holdings

Family office

Copenhagen · Pre-Seed–Late Stage · 48 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Novo Holdings invests to improve human health and the sustainability of society and the planet while generating attractive long-term returns for the Novo Nordisk Foundation. It focuses on life sciences and bio-sustainability, backing companies at all stages of development, from early-stage ventures through growth and public equities. Alongside significant direct investments, it maintains a broadly diversified capital investment allocation spanning equities, bonds, real estate, infrastructure and private equity. The firm positions itself as a responsible, values-driven investor aiming to deliver both strong financial returns and positive societal impact, operating with a long-term return perspective across global markets.

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Late Stage

Check

$1.1M – $54M

Copenhagen, DK

Instruments

Equity

Founded

1999

Last 12 months

5 investments

AUM

$108B

Tracked investments

Team · 48 people

from the firm's website & curated & public directories

Aaron Nelson· Partner· United Statesin

Aaron Nelson is a Partner in Novo Holdings' US Venture Investments unit, which he joined in June 2025. He was previously Managing Director at the Novartis Venture Fund, where he led Seed and Series A investments in therapeutic drug discovery, and contributed to Novartis's digital health investment program dRx Capital. Earlier he worked across Novartis Research & Development units including Trials of the Future and Investigative Toxicology. He holds a BA from Cornell University, a PhD in Cell and Microbiology from the University of Pennsylvania, and an MD from Tufts University, and conducted post-doctoral studies at the Karolinska Institutet.

Abhijeet Lele· Senior Partner· United States

Abhijeet Lele is Senior Partner and Head of US Principal Investments at Novo Holdings, which he joined in September 2020, with over 20 years of healthcare investment experience. He previously led US healthcare investing at Temasek and, before that, at Investor AB/Patricia Industries, and began his investing career at EGS Partners, a healthcare-focused hedge fund. Earlier in his career he was an Engagement Manager at McKinsey & Company and held operating roles in the pharmaceutical industry. He holds an MA in Natural Sciences from Cambridge University and an MBA from Cornell University.

Aleks Engel· Partner· Bostonin

Aleks Engel is a Partner in Novo Holdings' Planetary Health Investments team, based in Boston, having joined the firm in 2014 and previously worked on its Principal Investments and Seed Investments teams in Copenhagen. Before Novo Holdings, he held roles at Baxter International, Pfizer Global Research and Development, Thomson Scientific & Healthcare, and McKinsey & Company. He holds a PhD in Biochemical Engineering and an MSc in Chemical Engineering Practice from MIT.

Amer Sheikh· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

Amer Sheikh joined Novo Holdings Seed Investments as a Partner in January 2026, where he leads the firm's Quantum Technologies investment strategy, covering quantum computing and sensing, advanced computing, and enabling software and infrastructure. He previously worked as an Investment Director at HSBC Ventures leading its Quantum and Deep Tech themes, and held senior investment roles at Sky Ventures and Centrica Ventures. He holds a PhD in Physics from Loughborough University and the Institut Laue Langevin and a BSc (Hons) in Physics.

Amit Kakar· Managing Partner· Singaporein

Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia, leading investments and partnerships across China, Japan, Singapore, and Southeast Asia. He has over 25 years of healthcare experience, previously holding roles at Everlife Asia (Head of M&A and Business Development), the Avenue Capital Group (Head of healthcare investments for Asia), and GE Healthcare. He holds a medical degree with a postgraduate qualification in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

Anders Bendsen Spohr· Managing Partner, Head of Planetary Health Investments

Anders Bendsen Spohr joined Novo Holdings A/S in 2017 and serves as Managing Partner and Head of the Planetary Health Investments team. Before Novo Holdings, he held supply chain and operations leadership roles including VP of Global Product Supply at Xellia Pharmaceuticals, EVP of Global Product Supply at Leo Pharma, and VP of Global Supply Chain at Novozymes. He holds a PhD in Biotechnology and an MSc in Chemical Engineering from the Technical University of Denmark, along with a graduate diploma in Business Administration from Copenhagen Business School.

Andreas Nickelsen· Partner

Andreas Nickelsen is a Partner in Novo Capital Investors at Novo Holdings, having joined in March 2022. He holds an MSc in Economics from the University of Copenhagen and became a CFA Charterholder in 2011. Before Novo Holdings, he worked at Realdania, Sampension, and Ørsted.

Anna Fan· Senior Partner, Public Equity· San Francisco, Californiain

Anna Fan is a Senior Partner at Novo Holdings, where she leads the public investing strategy for the Venture Investments team and serves on the Life Sciences Operating Committee. Before joining the firm, she covered publicly traded biotech companies at Sectoral Asset Management and began her career in financial advisory serving fund managers and corporate clients in life sciences. She holds a Ph.D. and B.Sc. in Biochemistry from McGill University and is a CFA charterholder.

Christoffer Søderberg· Managing Partner

Managing Partner in Principal Investments and a member of the Executive and Life Science Leadership Teams.

Morten Beck Jørgensen· Managing Partner

Managing Partner in Capital Investments and a member of the Executive and Capital Investments Leadership Teams.

m•••@novo.dkreveal

Camilla Petrycer Hansen· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

c•••@novo.dkreveal

Emmanuelle Coutanceau· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

e•••@novo.dkreveal

Eric M. Snyder· Partner· Greater Bostonin

Eric M. Snyder is a Partner in Venture Investments at Novo Holdings. His investment focus includes medical devices and therapeutics.

e•••@novo.dkreveal

Helen Gaffney· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

h•••@novo.dkreveal

Henrik Kjær Hansen· Senior Partner

h•••@novo.dkreveal

Jeroen Bakker· Partner· Copenhagen, Capital Region of Denmark, Denmarkin

j•••@novo.dkreveal

Jørgen Søberg Petersen· Senior Partner· Utrecht, Utrecht, Netherlandsin

j•••@novo.dkreveal

Scott A. Beardsley· Managing Partner

s•••@novo.dkreveal

Søren Møller· Managing Partner· Copenhagen, Capital Region of Denmark, Denmarkin

s•••@novo.dkreveal

Aaron Nelson· Partner· Cambridge, Massachusettsin

Aaron Nelson is a Partner at Novo Holdings with a background spanning academic research, pharmaceutical development, and digital medicine. His current focus is therapeutic chemical and biological technologies.

a•••@novartis.comreveal

Jim Trenkle· Partner, Venture Investments· Cambridge, Massachusettsin 𝕏

Max Klement· Partner, Venture Investments· Amsterdam, Netherlandsin

Max Klement is a Partner in Venture Investments at Novo Holdings. He has an engineering background and experience in the global biotech industry, focusing on the development and translation of biomedical science toward human health applications.

Heath Lukatch· Partner· San Francisco, Californiain

Hongjie Hu· Partner· New York, New Yorkin

Hongjie Hu is a Partner in Growth Investments at Novo Holdings, where he focuses on investments at the intersection of healthcare, life sciences, and technology across North America, Europe, Israel, and Asia.

Alan Liu· Principal

Alan Liu is a Principal in the Planetary Health Investments department at Novo Holdings A/S, which he joined in 2020, where he works on deal sourcing, execution, and portfolio management. Before Novo Holdings, he worked in J.P. Morgan's European Healthcare team in London and its North Asia M&A team in Hong Kong, handling private and public transactions across multiple industries. He holds a BSc in Quantitative Finance from CUHK, an MPhil in Biotechnology from Cambridge, and an MSc in Integrated Immunology from Oxford.

Anders Lykke Iversen· Principal, Principal Investments· Copenhagen, Capital Region of Denmark, Denmarkin

Anders Lykke Iversen joined Novo Holdings in November 2017 as an Associate in Principal Investments and works on deal sourcing, execution, and portfolio management. Before Novo Holdings, he was a management consultant at Bain & Company in Copenhagen, focusing on due diligence and post-acquisition work for private equity clients and strategy, performance improvement, and M&A for Nordic corporates. He holds a BSc in International Business and an MSc in Finance & Strategic Management from Copenhagen Business School.

a•••@novo.dkreveal

Angela Jong· Principal· San Francisco Bay Areain

Angela Jong joined Novo Holdings in 2025 as a Principal on the Planetary Health Investments team. She was previously a Vice President at Advent International working on healthcare buyout investments, and earlier worked at Stellar Health, a healthcare technology startup, and at TA Associates on healthcare growth and buyout investments. She started her career in investment banking at Morgan Stanley.

Gábor Gyülvészi· Principal

g•••@novo.dkreveal

Daniel Rasmussen· Principal· Copenhagen, Denmarkin

Daniel Rasmussen is a Principal at Novo Holdings, the investment company managing assets for the Novo Nordisk Foundation. He leads fund-of-funds and co-investment activities in biotechnology, quantum technology, and planetary health, and brings experience from roles at BASF Venture Capital, Verdane, and Oaklins across venture capital, growth equity, and corporate finance.

Raymond Camahort· Principal· Boston, Massachusetts

Alex Grooten· Senior Manager, Head of Accounting· Copenhagen, Capital Region of Denmark, Denmarkin

Alex Grooten works at Novo Holdings in the Finance & Operations department, serving as Senior Manager, Head of Accounting.

Álvaro Gallego Jurado· Manager (Rewards Manager)

Álvaro Gallego Jurado joined Novo Holdings' People & Organisation department as a Rewards Manager in 2024, focusing on the governance of reward frameworks. He previously worked as a Performance & Rewards Partner Manager at Pandora A/S and gained earlier rewards experience at tech and security companies. A Spanish national, he holds an MChem in Chemistry and Materials Chemistry from the University of Edinburgh.

Amalie Stokkeland· Senior Associate· Los Angeles Metropolitan Areain

Amalie Stokkeland joined Novo Holdings A/S in February 2025 as a Senior Associate on the Planetary Health Investments team, where she works on deal sourcing, execution, and portfolio management. She previously worked in investment banking at ABG Sundal Collier on M&A and ECM transactions. She holds an MSc in Finance and a BSc in Economics and Business Administration from Aarhus University BSS.

Amy Kacprowicz· Senior Specialist· Bostonin

Amy Kacprowicz works at Novo Holdings US Inc. within the Strategy and People department. She joined Novo Ventures (US), Inc. as an Office Manager in Boston, then moved to the People & Organization team as an HR coordinator supporting HR operations in the Boston and San Francisco offices in 2023. She holds a Bachelor of Arts from Hobart and William Smith Colleges and a graduate certificate in Human Resources from Northeastern University, following earlier roles in healthcare administration.

Andeta Jonuzaj· Senior Specialist

Andeta Jonuzaj joined Novo Holdings in 2021 as a compliance specialist, dividing her time between the Finance and Ventures teams. She previously spent 12 years in the banking sector, handling financial closing controls, compliance tasks including Know Your Client, and reporting of various statements. She holds a Master's degree in Financial Management.

Anette Vium Sørensen· Tax Manager

Tax Manager within Finance & Operations.

Anne Dorte Stensberg Jensen· Executive Assistant, Principal Investments

Anne Dorte Stensberg Jensen joined Novo Holdings A/S as an Executive Assistant in the Principal Investments department in April 2024. She previously worked as a personal assistant at Copenhagen Infrastructure Partners and held PA and customer service roles at WS Audiology A/S. She holds a BA in German Business Communication from the University of Southern Denmark.

Barbara Fiorini· General Counsel, Executive Director

Barbara Fiorini is General Counsel at Novo Holdings A/S, which she joined in 2020, and has been part of the Executive Leadership Team since 2021, leading the legal department and handling the company's legal affairs across investments, divestments, and portfolio matters. She previously handled legal and compliance work for the Europe region at ISS World Services A/S and served as senior legal counsel at Genmab, including a period at Genmab US in New Jersey, and earlier worked as an M&A attorney at the law firm Plesner in Copenhagen. She holds a Master in Law from the University of Copenhagen and is a member of the Danish Bar Association.

Helle Bach· Chief People Officer· Copenhagen, Capital Region of Denmark, Denmarkin

Helle Bach joined Novo Holdings in 2025 as Chief People Officer, sitting within the Strategy & People organisation and on the Executive Leadership Team, and oversees the People & Organisation function across offices in Denmark, the US, London and APAC. She previously led the global HR function at DSV A/S, where she built the Group HR function and took part in company M&A, and earlier led the people area at Egmont International Holding after starting her career as a management consultant at Rambøll Management. She holds a Master of Political Science from Aarhus University (2001).

Kasim Kutay· CEO· UKin

Kasim Kutay has served as Chief Executive Officer of Novo Holdings A/S since September 2016 and sits on the Boards of Directors of Novo Nordisk A/S and Novonesis A/S. He was previously a Partner and member of the Global Management Committee at Moelis & Co. (2009–2016) and held various roles at Morgan Stanley from 1989 to 2007, including chair of the European Healthcare Group. He holds an MSc and BSc in Economics from the London School of Economics (LSE).

k•••@novo.dkreveal

Kasper Sobfeldt Jahn· Chief Strategy Officer· Houston, Texas, United Statesin

Kasper Jahn joined Novo Holdings in 2014 with the Principal Investments team, which handles healthcare buyout investments. He moved to lead the Strategy Office in 2021 and joined the Executive Leadership Team in 2025, taking on responsibility for People & Organisation. Before Novo Holdings, he was an Engagement Manager at McKinsey & Company in Copenhagen serving pharmaceutical and medical device companies, and he holds an MSc and PhD in Nanoscience from Aarhus University and is a CFA Charterholder.

Nigel Govett· CFO· Copenhagen, Capital Region of Denmark, Denmarkin

Nigel Govett has served as Chief Financial Officer of Novo Holdings A/S since March 2022, and sits on the Board of Directors of NNIT A/S as Chair of its Audit Committee. He previously held CFO roles at Oman Infrastructure Investment Management and the Sovereign Wealth Fund of Oman, and director positions at EQT and Close Brothers. A UK national, he is a Fellow of the ACCA and holds a BA (Hons) in Historical Studies from the University of Sunderland.

Avra van der Zee· Advisory Group Member· New York, New York, United Statesin

Avra van der Zee is a General Partner at SOSV, where she helps lead HAX's global climate investing strategy. She previously spent five years as COO of Elemental Impact, overseeing investments, communications, and operations, and earlier served as COO and General Counsel of JUMP (an SOSV investment) through its acquisition by Uber. She currently holds several board and advisory positions and focuses on helping founders scale hardware and climate technologies.

Kuang He· Vice President· Paris, Francein

Kuang He is a biotech venture capitalist and board observer at Booster Therapeutics.

Peter Eckes· Advisory Group Planetary Health· Europein

Peter Eckes is an operational partner at Astanor, which he joined in May 2023, where he works with the investment team and supports portfolio companies. He spent 32 years at BASF SE, including roles as CTO of its Agricultural Solutions R&D and Regulatory team and membership of the company's global Technology Leadership Team, with experience across agriculture, nutrition, specialty chemicals, and industrial biotechnology. His background covers R&D strategy, technology portfolio management, and large organizational transformations.

Thomas Vanderstichele· Associate· Londonin 𝕏

Heather Ludvigsen· Copenhagen, Denmarkin

Heather Ludvigsen is Senior Manager of Venture Investments at Novo Holdings A/S. She holds a CPA credential and has worked in corporate audit, internal audit, and financial reporting across external and internal functions. Her experience encompasses investment fund accounting, regulatory compliance, budgeting, and process controls review.

Kenneth Harrison· San Francisco, California

What they invest in

from 63 of 74 portfolio companies

Biotech ×52Healthtech ×33Medical Devices ×15Deep Tech ×9AI & Machine Learning ×8Digital Health ×7New Materials ×7Circular Economy ×5

HQs:United States×24Denmark×5United Kingdom×2Sweden×2Switzerland×1Finland×1

Investments · 74 tracked

founders shown can be your intro path

By year:2026 · 4 2025 · 4 2024 · 4 2023 · 5 2022 · 2 2021 · 221 dated

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLNApr 2026 · $300M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners Catalio Capital Management, LP F-Prime Capital InVivium Capital Norwest Venture Partners RiverVest Venture Partners +7 more

Bolt Biotherapeuticsboltbio.com in 𝕏NASDAQ: BOLT

Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells.

Co-investorsPfizer Venture Investments RA Capital Samsara BioCapital Sofinnova Ventures Vivo Capital Nan Fung Life Sciences +1 more

Hemab Therapeuticshemab.com in 𝕏NASDAQ: COAG

Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options.

BiotechHealthtech

Co-investorsAccess Biotechnology Avoro Capital Advisors HealthCap Sofinnova Partners

Biomasonbiomason.com in 𝕏Feb 2022✓ verified

Biomason uses biotechnology to grow biocement, producing concrete and tile products by using bacteria to bind natural materials as an alternative to Portland cement, aimed at concrete producers and the construction industry.

BiotechClimate TechConstruction TechNew MaterialsResearch Triangle Park, US

Ginger K. Dosier(Executive Officer, Director)Michael F. Noel(Director)John M. Dosier(Executive Officer)

Board seatAnders Bendsen Spohr· per SEC Form D

Co-investorsCarbon Celesta Capital Celesta Capital

Acesion Pharma ApSacesionpharma.com in✓ verified

Acesion Pharma is a biotech company developing pharmaceutical treatments.

BiotechHealthtechMedical DevicesCopenhagen, DK

Ulrik Sørensen(COO & Co-founder)Morten Grunnet(CSO & Co-founder)Anders Gaarsdal Holst(CEO & CMO)Torgeir Vaage(CFO)

Co-investorsAlpha Wave Global Canaan Partners Broadview Ventures Global BioAccess Fund

Amassamass.tech in✓ verified

Amass operates an agentic data platform that unifies over 500 million scientific documents — including research literature, patents, clinical trials, regulatory filings, and web sources — into a single engine that returns answers cited to their source.

AI & Machine LearningBiotechData & Infrastructure

Alexander Junge(Co-Founder & CTO)inHenrik Jensen(Co-Founder & CEO)in

Co-investorsGiant Ventures Global Llp Kost Capital

AvenCellavencell.com in 𝕏Oct 2024 · $112M✓ verified

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.

BiotechLongevityMedical Devices

Andrew Schiermeier(Chief Executive Officer)in

Co-investorsBlackstone Life Sciences Eight Roads Ventures F-Prime Capital NYBC Ventures

Boostertxboostertx.com in✓ verified

Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools.

BiotechDeep TechLongevity

Diogo R. Feleciano(Co-Founder & CSO)Darci J. Trader(Scientific Co-Founder / Advisor)João Ribas(Interim-CBO)

Co-investorsApollo Health Ventures Korify Capital

Calliotxcalliotx.com in✓ verified

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.

BiotechMedical DevicesSeattle, US

Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)

Co-investorsOmega Funds Frazier Life Sciences Jeito Capital Norwest Venture Partners

Clever Care Health Planclevercarehealthplan.com✓ verified

Clever Care is a culturally and linguistically sensitive Medicare Advantage health plan serving Southern California that integrates Eastern and Western medicine approaches.

HealthtechInsurTechSouthern California, US

Myong Sun Lee(Executive Officer, Director)Hiep Dinh Pham(Executive Officer, Director)Dave Firdaus(Executive Officer, Director)

Co-investorsNorwest Venture Partners Global Founders Capital GV (Google Ventures)AV8 Ventures Figure 8 Investments PruVen Capital Partners +1 more

Crystalystxcrystalystx.com in 𝕏✓ verified

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.

BiotechHealthtechMedical DevicesSan Diego, US

James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in

Co-investorsCatalys Pacific AN Venture Partners Frazier Life Sciences Lightstone Ventures Longwood Fund

Expeditiontxexpeditiontx.com in✓ verified

Expedition Therapeutics develops oral small-molecule treatments for inflammatory and respiratory diseases, with lead candidate EXPD-101, a once-daily DPP1 inhibitor for chronic obstructive pulmonary disease (COPD).

BiotechHealthtechSan Francisco, US

Co-investorsForbion Sofinnova Ventures Sanofi Ventures

LanzaTechlanzatech.com in 𝕏✓ verified

LanzaTech converts carbon-rich gases from industrial sources like steel mills and landfills into fuels and chemicals using synthetic biology.

Circular EconomyCleantechClimate Tech

Dr. Jennifer Holmgren(CEO)

Co-investorsActivant Capital Khosla Ventures Outset Ventures Qiming Venture Partners

NMD Pharmanmdpharma.com in 𝕏Nov 2023 · $81.3M✓ verified

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Co-investorsJeito Capital Roche Venture Fund Inkef

Revagenixrevagenix.com in✓ verified

Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs.

BiotechDeep TechHealthtechMedical Devices

Ryan Cirz(Co-founder & CEO)Andrew McCandlish(Co-founder & COO)Peter Smith(Chief Scientific Officer)Daniel Cloutier(VP, Development)

Co-investorsTenmile

The Ritedose Corporationritedose.com in✓ verified

Ritedose is a contract development and manufacturing organization (CDMO) and generic drug manufacturer specializing in sterile Blow-Fill-Seal (BFS) unit-dose delivery, producing medications such as inhalation and ophthalmic solutions.

Advanced ManufacturingBiotechHealthtechColumbia, US

Jody Chastain(CEO)

Co-investorsOlympus Partners

Verana Healthveranahealth.com in 𝕏✓ verified

Verana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.

AI & Machine LearningData & InfrastructureDigital HealthHealthtech

Sujay Jadhav(Chief Executive Officer)

Co-investorsBreyer Capital Tech Council Ventures Valspring Capital Define Ventures

ZELPzelp.co in✓ verified

ZELP develops technology to measure and reduce methane emissions from the livestock industry.

AgTechClimate TechImpact & Social GoodIoT

Francisco(Co-Founder, CEO)inPatricio(Co-Founder, Chairman of the Board)

Co-investorsCollaborative Fund Danone Manifesto Venture Starlight Ventures

AvailityJul 2021

HealthtechJacksonville, US

Nathan W. Eastman(Chief Financial Officer, Treasurer)Christopher Hunter(Director)Steve Betts(Director)Earnie Franklin(Director)Aaron Gani(Director)Carl McDonald(Director)

Board seatAbhijeet Lele· per SEC Form D

Co-investorsFrancisco Partners

Genomaticagenomatica.com in 𝕏Aug 2021SEC filingmedium confidence

Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.

BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US

Christophe Schilling(Co-founder (former CEO))Bernhard Palsson(Co-founder)Thomas McDonald(Executive Officer)Carlos A. Cabrera(Executive Chairman)John G. Gugel(Chief Executive Officer)Tom McDonald(SVP, Finance & Chief Financial Officer)

Board seatAnders Bendsen Spohr· per SEC Form D · $119.1M raise · filed Aug 2021

Co-investorsVantagePoint Capital Partners Casdin Capital

MycoWorksmycoworks.com in 𝕏Apr 2022

MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.

BiotechCircular EconomyNew MaterialsEmeryville, US

Philip Ross(Director)Michael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)

BoardKiersten Stead(Director)inThomas Grotkjaer(Director)

Board seatAnders Bendsen Spohr· per SEC Form D

Co-investorsDCVC (Data Collective)Hemisphere Ventures LLC Wireframe Ventures 8VC AgFunder DCVC Bio +3 more

Acesion Pharma

Developing a next generation antiarrhythmic drug that targets the SK channel to treat atrial fibrillation without causing significant adverse events.

Co-investorsGlobal BioAccess Fund

Adcendo ApSadcendo.com

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVida Ventures HealthCap Jeito Capital OrbiMed Pontifax Venture Capital RA Capital +2 more

Agnext

Planetary Health Investments, Asia; invested October 2024

Alentisalentis.ch in

Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis.

BiotechHealthtech

Co-investorsAvego BioScience Capital BioMedPartners Catalio Capital Management, LP Frazier Life Sciences Jeito Capital Longitude Capital +3 more

AMSilkamsilk.com in

AMSilk develops biogenic silk protein materials designed with AI-powered protein design and produced through precision fermentation, aimed at replacing conventional materials with lower-impact alternatives.

BiotechCircular EconomyNew Materials

AnaCardioanacardio.com

AnaCardio is a clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, including its GOAL-HF1 program for patients with Heart Failure and Reduced Ejection Fraction (HFrEF).

BiotechMedical DevicesStockholm, SE

Co-investors3B Future Health Fund Industrifonden Pureos Bioventures Sound Bioventures

Antag Therapeuticsantagtherapeutics.com in

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

Jens Juul Holst(Founder)Mette Rosenkilde(Founder)

Co-investorsBroadview Ventures SR One Capital Management

Aquafortus

Planetary Health Investments; invested February 2023

Asgard Therapeuticsasgardthx.com in 𝕏

Asgard Therapeutics is a biotech company developing cancer immunotherapies using direct cell reprogramming and gene therapy, with a lead program (AT-108) built as an off-the-shelf gene therapy.

BiotechHealthtech

Co-investorsIndustrifonden LU Innovation Boehringer Ingelheim Venture Fund

Augustine Therapeuticsaugustinetx.com in

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.

BiotechMedical Devices

Co-investorsAdBio partners Jeito Capital PMV V-Bio Ventures Asabys Partners

Avalyn

Venture Investments, North America; invested February 2017

Bactolife

Planetary Health Investments, Europe; invested March 2021

BBI Solutionsbbisolutions.com

BBI Solutions develops and manufactures native and recombinant reagents, antibodies, antigens, enzymes, and gold nanoparticle conjugates for in-vitro diagnostics (IVD) and life sciences teams.

Advanced ManufacturingBiotechMedical Devices

Benchmark Geneticsbmkgenetics.com in 𝕏

Benchmark Genetics develops and supplies high-performance Atlantic salmon ova and provides genetics and genotyping services for aquaculture producers worldwide, supporting breeding program design and genomic selection.

AgTechBiotechFoodTech

Kristian Botnen(CEO)

BGV

Venture Investments, Europe; invested December 2020

BioGeneration Venturesbiogenerationventures.com

BioGeneration Ventures is a venture capital investor focused on early-stage biotech and life sciences companies.

Biotech

Co-investorsBOM KfW Capital

Bluejay Therapeutics inMay 2024 · $182M

Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.

San Mateo, US

Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)

Co-investorsFrazier Life Sciences RA Capital RiverVest Venture Partners HBM Healthcare Investments T. Rowe Price Wellington Management

Checkmate Pharmaceuticals

Activating the immune system to recognize and destroy tumor cells.

BiotechCambridge, US

Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)

Co-investorsF-Prime Capital Sofinnova Ventures Longitude Capital

Chromologicschromologics.com inMar 2023

Chromologics develops natural red colorants as alternatives to synthetic dyes.

BiotechFoodTechNew MaterialsCopenhagen, DK

Anders Odum(Founder)

Co-investorsBlue Horizon Corporation Collateral Good Nordic Foodtech VC Doehler Ventures

Cirius Therapeuticsciriustx.com

Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.

BiotechDigital HealthGrand Rapids, US

Jerry Callahan(Executive Officer)Brian Farmer(Executive Officer)Robert Baltera(Executive Officer, Director)Howard Dittrich(Executive Officer)

BoardMichael Jandernoa(Director)Mark Olesnavage(Executive Officer)

Co-investorsFrazier Healthcare Partners

Claris Bioclarisbio.com inJul 2026

Claris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options.

BiotechHealthtech

Co-investorsRA Capital Sofinnova Ventures

Claris Biotherapeutics

BiotechJersey City, US

Henry Rath(Executive Officer)Susan Orr(Executive Officer)Clarke Atwell(Executive Officer, Director)Stephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)

Co-investorsCatalio Capital Management Samsara BioCapital Sofinnova Ventures

Clasp Therapeuticsclasptx.com in

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LP Cure Ventures Vivo Capital Catalio Capital Management Third Rock Ventures

Coave Therapeuticscoavetx.com in

Coave Therapeutics is a biotech company developing gene therapies based on AAV vector engineering and genetic construct design, targeting neurodegenerative and ocular diseases.

BiotechHealthtechParis, FR

Co-investorsFund+Kurma Partners Seroba Life Sciences V-Bio Ventures Bpifrance Invus +1 more

Coultreoncoultreon.com inApr 2026 · $125M

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)

Co-investorsLongwood Fund Sofinnova Ventures BAM Elevate Finchley Healthcare Ventures Forbion Luma Group +1 more

Doctor Anywheredoctoranywhere.com inDec 2023

Doctor Anywhere is a technology-driven healthcare company that provides medical care to patients through online and in-person channels.

Digital HealthHealthtechMental Health

Co-investorsOSK Ventures International Square Peg Capital

Esco Lifesciences Groupescolifesciences.com in 𝕏

Esco Lifesciences manufactures laboratory and biopharma equipment, including clean air, containment, and laboratory technologies, as well as IVF/ART medical devices for clinical and industrial laboratories, pharmaceutical companies, and fertility care providers.

BiotechHardwareMedical Devices

Co-investorsVivo Capital GIC

Genomegenomemedical.com in 𝕏

Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.

BiotechDigital HealthHealthtech

Mark Sylvester(Chief Financial Officer)Andrew Warner(Vice President, Product)Monica Zarb(Vice President, Business Development)Durand Van Arnem(Vice President, Engineering)Alan Rope(Medical Director)

Co-investorsCanaan Partners Dreamers VC Echo Health Ventures GV (Google Ventures)Illumina Ventures Kaiser Permanente Ventures +3 more

GlycoEraglycoera.com in 𝕏

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5AM Ventures Catalio Capital Management, LP LifeArc Ventures Roche Venture Fund Sixty Degree Capital Sofinnova Partners +1 more

HPNowhpnow.eu inSep 2023

HPNow produces hydrogen peroxide (Peroxide UltraPure) on-site through a patented electrochemical process that converts water, electricity, and air into low-concentration, high-purity peroxide for water treatment.

AgTechCircular EconomyCleantechHardwareNew Materials

Co-investorsAP Ventures Evonik Venture Capital GmbH

HST Pathwayshstpathways.com in 𝕏

HST Pathways provides an all-in-one software platform for ambulatory surgery centers (ASCs), covering scheduling, clinical operations (EMR), patient estimates and payments, billing, and data analytics across the full surgical case lifecycle.

Digital HealthHealthtechSaaS

Co-investorsBain Capital Tech Opportunities Blue Hour Ventures

Hummingbird Biosciencehummingbirdbioscience.com in 𝕏

Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.

AI & Machine LearningBiotechDeep TechHealthtech

Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Konrad Paszkiewicz(Chief Technology Officer)Kwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)

Co-investorsAltium Capital ClavystBio Decheng Capital Droia Ventures Frazier Life Sciences Kiwoom Investment +2 more

Inspirnainspirna.com in 𝕏

Inspirna is a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, including oral small molecules and biologics that target newly discovered drivers of metastasis in common cancers such as colorectal, non-small cell lung, and endometrial cancer.

BiotechHealthtechNew York, US

Co-investorsSofinnova Partners Start Capital Vivo Capital Sands Capital Ventures

Kebotixkebotix.com in 𝕏

Kebotix uses artificial intelligence, machine learning, and laboratory automation to discover and develop new materials and molecules.

AI & Machine LearningDeep TechNew MaterialsCambridge, US

Dennis Sheberla(Executive Officer)Semion Saykin(Executive Officer)Alan Aspuru-Guzik(Executive Officer)inAshish Kulkarni(Executive Officer, Director)

BoardTong Hui(Director)Andrew Krowne(Director)in

Co-investorsArcTern Ventures Bantam Group Flybridge Capital Partners One Way Ventures Propagator Ventures Safar Partners +3 more

Kivu Biosciencekivubioscience.com inOct 2024 · $92M

Kivu Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, using site-specific conjugation technology to create more stable and homogeneous cancer therapies with reduced off-tumor toxicity.

BiotechDeep TechHealthtech

Mohit Trikha(CEO)

Co-investorsBOM HealthCap M Ventures Red Tree Venture BioGeneration Ventures

LimmaTech Biologicsacquired by Lilly

Portfolio company acquired by Lilly

MinervaXminervax.com inOct 2023

MinervaX is a clinical-stage biotech company developing a prophylactic vaccine against Group B Streptococcus, with a lead candidate (AlpN GBS) in clinical trials for use in pregnancy and older adults.

BiotechHealthtech

Co-investorsAdjuvant Capital Industrifonden LU Innovation OrbiMed Pureos Bioventures Sanofi Ventures +2 more

Myricx Biomyricxbio.com in

Myricx is a biotech company developing a new class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferase (NMT) enzymes, aimed at treating cancer.

BiotechMedical DevicesLondon, GB

Co-investorsBrandon Capital Partners Sofinnova Partners

Newleos Therapeuticsnewleostherapeutics.com inFeb 2025 · $93.5M

BiotechBoston, US

David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in

BoardChristoph Westphal(Director)Ming Cheah(Director)Raymond Camahort(Director)

Co-investorsDCVC (Data Collective)DCVC Bio Longwood Fund

Novo Nordisknovonordisk.com in 𝕏

Novo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies.

BiotechHealthtechCopenhagen, DK

Maziar Mike Doustdarin

Co-investorsHM Venture Partners

Novonesisnovonesis.com in

Oxboxb.com in

OXB is a contract development and manufacturing organization (CDMO) providing end-to-end services for cell and gene therapies, with expertise in lentiviral vectors, AAV, adenovirus, and other viral vector manufacturing.

BiotechDeep TechHealthtechOxford, GB

Co-investorsOberland Capital

Qurequre.ai in 𝕏

Qure.ai builds deep learning and AI software to detect and manage diseases such as lung cancer, tuberculosis, pediatric TB, and stroke, with several FDA-cleared solutions.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investorsCrane Venture Partners Lightspeed Venture Partners HealthQuad Kae Capital Merck Global Health Innovation Fund Sequoia Capital

Rapptarappta-therapeutics.com

Rappta Therapeutics develops a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor enzyme PP2A (protein phosphatase 2A).

BiotechHealthtech

Co-investorsAdvent Life Sciences Novartis Venture Fund

Raytherapeuticsraytherapeutics.com

Co-investorsNorwest Venture Partners

Recursionrecursionpharma.com in 𝕏

Recursion applies artificial intelligence and large-scale data analysis to accelerate drug discovery and development.

AI & Machine LearningBiotechDeep TechMedical DevicesSalt Lake City, US

Chris Gibson(Co-founder, Chairman of the Board)

Co-investorsDCVC (Data Collective)Lux Capital Baillie Gifford Air Street Capital Amplify Partners Catalio Capital Management, LP +8 more

Reunion Neurosciencereunionneuro.com in 𝕏Sep 2025 · $103M

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.

BiotechDigital HealthMental HealthMorristown, US

Sahil V. Kirpekar(President and CEO)Gregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in

Co-investorsFemHealth Ventures Mitsui Global Investment MPM BioImpact

SiteOne TherapeuticsDec 2024

Deep tech company; invested from Fund I in 2015

BiotechBozeman, US

Justin DuBois(Director)George Miljanich(Executive Officer)Stan Abel(Executive Officer, Director)

BoardWill Price(Director)inLowell Sears(Director)Joseph Zakrzewski(Director)

Co-investorsNext Frontier Capital Mission Biocapital OrbiMed

Supira Medicalsupiramedical.com inMar 2025 · $120M

Supira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock.

HardwareHealthtechMedical DevicesCampbell, US

Nitin Salunke(President & CEO)Jean Orth(Executive Officer)Mariam Maghribi(Executive Officer, Director)

BoardCasey Gordon(Director)Christopher Shen(Director)Bihua Chen(Director)

Co-investors415 Capital Amed Ventures The Capital Partnership Unorthodox Ventures

Terremotobioterremotobio.comApr 2026 · $108M

Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas.

BiotechDeep TechSouth San Francisco, US

Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)

BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)

Co-investorsEcoR1 Capital OrbiMed RA Capital Osage University Partners Third Rock Ventures

Tribune Therapeutics ABtribunetx.com inMar 2025

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.

BiotechHealthtech

Ole Kaasbøll(Co-founder)

Co-investorsHealthCap Industrifonden LifeArc Ventures Investinor

Wcgclinicalwcgclinical.com in 𝕏

WCG provides clinical trial services including institutional review board (IRB) review, site enablement, data and insights, and AI-enabled software for sponsors, CROs, and research sites.

AI & Machine LearningBiotechHealthtech

Co-investorsLeonard Green

Windward Biowindwardbio.com in

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOrbiMed Quan Capital RA Capital Sanofi Ventures SR One Capital Management Janus Henderson Investors +3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 4

IPOs and acquisitions across the tracked portfolio

Avalyn Pharma IncNASDAQ: AVLNBolt BiotherapeuticsNASDAQ: BOLTHemab TherapeuticsNASDAQ: COAGLimmaTech Biologicsacq. by Lilly

Portfolio news

latest coverage across their companies

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Terremotobio · fiercebiotech.com · Aug 12, 2026

RXRX Stock | Recursion Pharmaceuticals, Inc Price, Quote, News & Analysis - TipRanks.com

Recursion · tipranks.com · Aug 11, 2026

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease - BioSpace

BioGeneration Ventures · biospace.com · Aug 5, 2026

Claris Biotherapeutics Raises $118M in Series B Funding

Claris Biotherapeutics · finsmes.com · Aug 3, 2026

Claris Bio raises $118M to advance first-ever LSCD therapy

Claris Bio · glance.eyesoneyecare.com · Aug 3, 2026

NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness | The Manila Times

NMD Pharma · manilatimes.net · Jul 23, 2026

Pain drugmaker Latigo outlines plans to go public | BioPharma Dive

SiteOne Therapeutics · biopharmadive.com · Jul 20, 2026

Forward Financing $525 Million: VFN + ABS Deal Explained

Clever Care Health Plan · funderintel.com · Jul 16, 2026

Frequently asked questions

How many investments has Novo Holdings made?: Novo Holdings has 28 tracked investments, 1 of which have exited via acquisition or IPO, including 1 dated in the last 24 months.
What stage does Novo Holdings invest at?: Novo Holdings invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Novo Holdings's typical check size?: Novo Holdings typically writes checks of $1.1M – $54M.
What sectors does Novo Holdings focus on?: Novo Holdings focuses on AgTech, Biotech, Cleantech, Climate Tech, Digital Health, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.
Where is Novo Holdings located?: Novo Holdings is headquartered in Copenhagen, DK.
Does Novo Holdings lead rounds?: Novo Holdings has led 7 of the 14 rounds where its role is on record.
Who does Novo Holdings co-invest with?: Novo Holdings most often shares deals with Jeito Capital, Industrifonden, OrbiMed, among 41 tracked co-investors.

Images

Co-investors · 10

Canaan Partners

Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.

Both backed · 2

Acesion Pharma ApS Genome

$500K – $20M

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 2

GlycoEra NMD Pharma

$648K – $3.2M

MPM BioImpact

MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.

Both backed · 1

Reunion Neuroscience

$1M – $15M

Apollo Health Ventures

Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.

Both backed · 1

Boostertx

Uncork Capital

Uncork Capital (formerly SoftTech VC) is a seed-stage venture firm that invests early in founders, with a focus on AI-native companies building leverage and scale.

$3M – $5M

Xfund

Xfund is a venture capital partnership connecting leading VC firms with top research universities in the US and abroad, backing entrepreneurs with multidisciplinary backgrounds building technology companies.

$50K – $500K

JAZZ Venture Partners

JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.

$100K – $20M

Abingworth

Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.

$15M – $30M

6 Dimensions Capital

6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.

Bain Capital Life Sciences

Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.

Firms observed investing alongside Novo Holdings, from public investor directories. Shared companies are the overlap with Novo Holdings's recorded portfolio.

Similar investors

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

$540K – $27M

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

$5K – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Better Ventures Central Llc

Better Ventures is an early-stage venture capital firm backing mission-driven technology companies working to build a better world across climate, health, and workforce sectors.

$500K – $1.5M

BDC Fund Investments (Fund-of-Funds)

BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner, backing emerging and established fund managers who invest in technology-focused Canadian companies.

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Pre-Seed Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States